Royal Bank of Canada’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-462
| Closed | -$9K | – | 7100 |
|
|
2023
Q3 | $9K | Sell |
462
-13,545
| -97% | -$301K | ﹤0.01% | 6441 |
|
|
2023
Q2 | $336K | Sell |
14,007
-4,589
| -25% | -$111K | ﹤0.01% | 4269 |
|
|
2023
Q1 | $408K | Sell |
18,596
-22,501
| -55% | -$566K | ﹤0.01% | 4038 |
|
|
2022
Q4 | $1.03M | Sell |
41,097
-2,727
| -6% | -$67.8K | ﹤0.01% | 3482 |
|
|
2022
Q3 | $1.08M | Sell |
43,824
-34,566
| -44% | -$881K | ﹤0.01% | 3393 |
|
|
2022
Q2 | $1.69M | Sell |
78,390
-6,908
| -8% | -$152K | ﹤0.01% | 3036 |
|
|
2022
Q1 | $2.38M | Sell |
85,298
-9,433
| -10% | -$279K | ﹤0.01% | 2901 |
|
|
2021
Q4 | $3.65M | Sell |
94,731
-15,645
| -14% | -$667K | ﹤0.01% | 2619 |
|
|
2021
Q3 | $5.04M | Buy |
110,376
+5,334
| +5% | +$249K | ﹤0.01% | 2280 |
|
|
2021
Q2 | $5.25M | Buy |
105,042
+15,629
| +17% | +$765K | ﹤0.01% | 2285 |
|
|
2021
Q1 | $4.59M | Sell |
89,413
-5,706
| -6% | -$312K | ﹤0.01% | 2300 |
|
|
2020
Q4 | $4.72M | Buy |
95,119
+3,401
| +4% | +$153K | ﹤0.01% | 2223 |
|
|
2020
Q3 | $3.58M | Sell |
91,718
-832
| -0.9% | -$33.9K | ﹤0.01% | 2228 |
|
|
2020
Q2 | $4M | Sell |
92,550
-56,251
| -38% | -$2.15M | ﹤0.01% | 2107 |
|
|
2020
Q1 | $4.36M | Buy |
148,801
+31,870
| +27% | +$1.1M | ﹤0.01% | 1904 |
|
|
2019
Q4 | $4.45M | Sell |
116,931
-31,495
| -21% | -$937K | ﹤0.01% | 2240 |
|
|
2019
Q3 | $3.54M | Buy |
148,426
+31,709
| +27% | +$862K | ﹤0.01% | 2322 |
|
|
2019
Q2 | $3.36M | Buy |
116,717
+18,757
| +19% | +$524K | ﹤0.01% | 2364 |
|
|
2019
Q1 | $2.79M | Buy |
97,960
+20,798
| +27% | +$545K | ﹤0.01% | 2444 |
|
|
2018
Q4 | $1.79M | Buy |
77,162
+18,406
| +31% | +$502K | ﹤0.01% | 2738 |
|
|
2018
Q3 | $2.03M | Buy |
58,756
+4,200
| +8% | +$142K | ﹤0.01% | 2838 |
|
|
2018
Q2 | $1.78M | Buy |
54,556
+1,938
| +4% | +$63.7K | ﹤0.01% | 2819 |
|
|
2018
Q1 | $1.73M | Buy |
52,618
+7,678
| +17% | +$251K | ﹤0.01% | 2788 |
|
|
2017
Q4 | $1.28M | Buy |
44,940
+17,037
| +61% | +$477K | ﹤0.01% | 3068 |
|
|
2017
Q3 | $813K | Buy |
27,903
+2,079
| +8% | +$53.8K | ﹤0.01% | 3398 |
|
|
2017
Q2 | $620K | Buy |
25,824
+3,969
| +18% | +$88.9K | ﹤0.01% | 3499 |
|
|
2017
Q1 | $507K | Sell |
21,855
-15,728
| -42% | -$334K | ﹤0.01% | 3626 |
|
|
2016
Q4 | $692K | Buy |
37,583
+23,534
| +168% | +$469K | ﹤0.01% | 3468 |
|
|
2016
Q3 | $318K | Buy |
14,049
+3,493
| +33% | +$71.6K | ﹤0.01% | 4087 |
|
|
2016
Q2 | $190K | Buy |
10,556
+8,601
| +440% | +$169K | ﹤0.01% | 4440 |
|
|
2016
Q1 | $37K | Buy |
1,955
+1,080
| +123% | +$20.9K | ﹤0.01% | 5251 |
|
|
2015
Q4 | $25K | Buy |
875
+184
| +27% | +$5.32K | ﹤0.01% | 5613 |
|
|
2015
Q3 | $18K | Buy |
+691
| New | +$23.4K | ﹤0.01% | 5603 |
|
Other funds holding BBC
FDCDDQ
DI
DWS
DSC
Royal Bank of Canada's BBC Position: Q4 2023 in Review
Royal Bank of Canada sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2023, closing a stake of 462 shares — an estimated $9K sold.
Royal Bank of Canada first reported a position in BBC in Q3 2015 and held it in 33 quarters. The position peaked at $5.25M in Q2 2021. 18 funds tracked by Wall St. Rank hold BBC as of Q4 2023.
- Royal Bank of Canada reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2023 after selling out during the quarter.
- Royal Bank of Canada sold 462 Virtus Biotech Clinical Trials ETF shares in Q4 2023, an estimated $9K.
- Royal Bank of Canada first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2015 and held it in 33 quarters.
- Royal Bank of Canada's Virtus Biotech Clinical Trials ETF position peaked at $5.25M in Q2 2021.
- 18 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2023.
Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.